Shares of Mast Therapeutics, Inc. (NASDAQ:SVRA) have been given a consensus broker rating score of 1.67 (Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and two have given a strong buy rating to the company. Mast Therapeutics’ rating score has improved by 16.5% from 90 days ago as a result of various analysts’ ratings changes.

Analysts have set a 1 year consensus target price of $19.00 for the company, according to Zacks. Zacks has also assigned Mast Therapeutics an industry rank of 88 out of 265 based on the ratings given to its competitors.

Several equities research analysts have recently weighed in on SVRA shares. Zacks Investment Research raised Mast Therapeutics from a “hold” rating to a “buy” rating and set a $6.50 price target for the company in a research note on Wednesday, August 16th. Canaccord Genuity reissued a “buy” rating and issued a $18.00 price target on shares of Mast Therapeutics in a research note on Monday, July 17th. Finally, JMP Securities started coverage on Mast Therapeutics in a research note on Monday, September 11th. They issued an “outperform” rating and a $20.00 price target for the company.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at

Shares of Mast Therapeutics (NASDAQ SVRA) traded down 3.0000% during trading on Monday, reaching $8.2935. The company’s stock had a trading volume of 238,161 shares. The firm’s market cap is $200.73 million. Mast Therapeutics has a 12 month low of $4.60 and a 12 month high of $43.05. The company’s 50 day moving average price is $6.04 and its 200 day moving average price is $5.99.

About Mast Therapeutics

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.

Get a free copy of the Zacks research report on Mast Therapeutics (SVRA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with's FREE daily email newsletter.